PDE4D and fragile X syndrome: BPN14770 is a selective small molecule allosteric inhibitor of PDE4D that was granted Orphan Drug Designation by the Food and Drug Administration (FDA) upon successful completion of a Phase 2 trial in Fragile X syndrome (FXS).